IDEAYA Biosciences Dirección

Dirección controles de criterios 1/4

El CEO de IDEAYA Biosciences es Yujiro Hata , nombrado en Jun 2015, tiene una permanencia de 9.42 años. compensación anual total es $6.00M, compuesta por 10% salario y 90% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.78% de las acciones de la empresa, por valor de €17.17M. La antigüedad media del equipo directivo y de la junta directiva es de 1.9 años y 6 años, respectivamente.

Información clave

Yujiro Hata

Chief Executive Officer (CEO)

US$6.0m

Compensación total

Porcentaje del salario del CEO	10.0%
Permanencia del CEO	9.4yrs
Participación del CEO	0.8%
Permanencia media de la dirección	1.9yrs
Promedio de permanencia en la Junta Directiva	6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Yujiro Hata en comparación con los beneficios de IDEAYA Biosciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$178m
Jun 30 2024	n/a	n/a	-US$154m
Mar 31 2024	n/a	n/a	-US$129m
Dec 31 2023	US$6m	US$598k	-US$113m
Sep 30 2023	n/a	n/a	-US$103m
Jun 30 2023	n/a	n/a	-US$74m
Mar 31 2023	n/a	n/a	-US$68m
Dec 31 2022	US$3m	US$570k	-US$59m
Sep 30 2022	n/a	n/a	-US$53m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$4m	US$544k	-US$50m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$30m
Mar 31 2021	n/a	n/a	-US$31m
Dec 31 2020	US$2m	US$510k	-US$34m
Sep 30 2020	n/a	n/a	-US$40m
Jun 30 2020	n/a	n/a	-US$46m
Mar 31 2020	n/a	n/a	-US$44m
Dec 31 2019	US$2m	US$457k	-US$42m
Sep 30 2019	n/a	n/a	-US$40m
Jun 30 2019	n/a	n/a	-US$42m
Mar 31 2019	n/a	n/a	-US$38m
Dec 31 2018	US$2m	US$420k	-US$34m

Compensación vs. Mercado: La compensación total de Yujiro($USD6.00M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.64M).

Compensación vs. Ingresos: La compensación de Yujiro ha aumentado mientras la empresa no es rentable.

CEO

Yujiro Hata (50 yo)

9.4yrs

Permanencia

US$5,995,440

Compensación

Mr. Yujiro S. Hata serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences, Inc. and has been its Chief Executive Officer, Presiden...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Yujiro Hata	President	9.4yrs	US$6.00m	0.78% € 17.2m
Andres Briseno	Principal Accounting Officer	3.8yrs	US$1.41m	0.028% € 621.4k
Michael White	Chief Scientific Officer	3yrs	US$2.76m	sin datos
Darrin Beaupre	Chief Medical Officer	2yrs	US$1.81m	0% € 0
Paul Barsanti	Chief Technology Officer	1.8yrs	sin datos	sin datos
Douglas Snyder	Senior VP & General Counsel	less than a year	sin datos	sin datos
Francine Zelaya	Vice President & Head of Human Resources	less than a year	sin datos	sin datos
Mick O'Quigley	Chief of Staff & Clinical Development	2.7yrs	sin datos	sin datos
Daniel Simon	Chief Business Officer	less than a year	sin datos	sin datos
Stu Dorman	Chief Commercial Officer	no data	sin datos	sin datos

1.9yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 30J no se considera experimentado ( 1.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yujiro Hata	President	9.4yrs	US$6.00m	0.78% € 17.2m
Wendy Yarno	Independent Director	4.9yrs	US$358.02k	0% € 0
Jeffrey Stein	Independent Director	9.1yrs	US$363.02k	0.0050% € 108.4k
Susan Kelley	Independent Director	3.8yrs	US$349.52k	0% € 0
Frank McCormick	Chair of Scientific Advisory Board	5.8yrs	sin datos	sin datos
Scott William Morrison	Independent Director	6.3yrs	US$364.52k	0% € 0
Catherine Mackey	Independent Director	2.6yrs	US$350.52k	0% € 0
Trey Ideker	Member of Scientific Advisory Board	8.5yrs	sin datos	sin datos
William Sellers	Member of Scientific Advisory Board	5.8yrs	sin datos	sin datos
Elizabeth Swisher	Member of Scientific Advisory Board	8.5yrs	sin datos	sin datos
Terry Rosen	Independent Chairman of the Board	8.8yrs	US$369.52k	0.019% € 414.0k
Malcolm Hampton	Independent Director	4.4yrs	US$349.52k	0% € 0

6.0yrs

Permanencia media

67.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 30J se considera experimentada (6 años de antigüedad promedio).

IDEAYA Biosciences Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

Recent updates

IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer

New minor risk - Revenue size

IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors

IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Full year 2023 earnings released: US$1.96 loss per share (vs US$1.42 loss in FY 2022)

New major risk - Shareholder dilution

IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.04 profit in 3Q 2022)

IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline

New minor risk - Share price stability

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

IDEAYA Biosciences, Inc. Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo) Adjuvant Uveal Melanoma

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.50 loss per share (vs US$0.57 loss in 2Q 2022)

IDEAYA Biosciences, Inc. Appoints Andres Ruiz Briseno as Principal Accounting Officer

New major risk - Shareholder dilution

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.36 loss in 1Q 2022)

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.41 loss in FY 2021)

IDEAYA Biosciences, Inc. Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces Board Appointments

IDEAYA Biosciences, Inc Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161

IDEAYA Biosciences, Inc. Appoints Darrin M. Beaupre as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline

Third quarter 2022 earnings released: EPS: US$0.04 (vs US$0.31 loss in 3Q 2021)

IDEAYA Biosciences, Inc. Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors

IDEAYA Biosciences, Inc. Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma

IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-In-Class Pol Theta Helicase Inhibitor Development Candidate

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.33 loss in 2Q 2021)

IDEAYA Biosciences, Inc. Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors

IDEAYA Biosciences, Inc. Announces Development Candidate Nomination of Potential First-In-Class Pol Theta Helicase Inhibitor in Collaboration with GSK

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 2000 Growth Index

IDEAYA Biosciences, Inc. Appoints Catherine Mackey to its Board of Directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

IDEAYA Biosciences, Inc. Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License

IDEAYA Biosciences, Inc. Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma

Director Yujiro Hata has joined 3rd company board

IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort

New 90-day high: €17.80

IDEAYA Biosciences, Inc. Appoints Susan L. Kelley to its Board of Directors

New 90-day high: €16.40

IDEAYA Biosciences, Inc. Announces Appointment of Matthew Maurer as Head of Clinical Oncology and Medical Affairs

New 90-day high: €16.30

Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry

IDEAYA Biosciences, Inc. Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA

IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor

New 90-day low: €10.10

Nasdaq Biotechnology Index Selects IDEAYA Biosciences, Inc

New 90-day high: €12.70

IDEAYA Biosciences, Inc. and Pfizer Inc. Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations

IDEAYA Biosciences, Inc. Names Garret Hampton to the Nominating and Corporate Governance Committee

IDEAYA Biosciences, Inc. announced that it has received $19.999995 million in funding from Glaxosmithkline Intellectual Property (No.4) Limited

Análisis de compensación del CEO

CEO

Permanencia

Compensación